- Home
- SST vs ANVS Comparison
SST vs ANVS Comparison
Compare SST & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | ANVS |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 111.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SST | ANVS |
|---|---|---|
| Price | $2.80 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $13.50 |
| AVG Volume (30 Days) | 7.8K | ★ 314.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $1.11 |
| 52 Week High | $11.30 | $5.50 |
Technical Indicators
Market Signals| Indicator | SST | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 29.72 | 46.57 |
| Support Level | $0.34 | $2.27 |
| Resistance Level | $3.57 | $2.63 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 13.83 | 34.62 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.